Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Reports 15-Percent Spike in Q3 Bio-Analytical Revenues

NEW YORK (GenomeWeb News) – Agilent Technologies yesterday reported a 15-percent increase in third-quarter revenues for its Bio-Analytical Measurement business as deliveries of new products accelerated, the company said.
 
For the third fiscal quarter ended July 31, Agilent reported $391 million in revenues for the Bio-Analytical business, a 15-percent spike from $341 million in the same quarter last year. The company said it recorded $387 million in orders in Q3, an 11-percent increase from $348 million one year ago.
 
Agilent said that Life Sciences orders increased 13 percent, while Chemical Analysis orders jumped 10 percent over the year-ago period. The company said that “robust” growth in Asia and Europe was balanced by single-digit growth in the Americas due to ongoing weakness from traditional large pharmaceutical companies.
 
Agilent Technologies’ total revenues for Q3 increased 17 percent to $1.45 billion from $1.24 billion in the same quarter last year. The company’s net income rose 118 percent to $227 million from $104 million a year ago.
 
Agilent spent $186 million on R&D in Q3 2006, compared with $183 million in the third quarter of 2005.
 

As of July 31, Agilent said it had $2.3 billion in cash and cash equivalents on hand.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.